IBRNvsSBIOETF Comparison
VS
iShares Neuroscience and Healthcare ETF (IBRN) belongs to the Healthcare Technology segment. ALPS Medical Breakthroughs ETF (SBIO) is part of the Tomorrow's Treatments segment. Both ETFs have the same top 2 sector exposures: Healthcare and Non-Corporate. IBRN is less expensive with a Total Expense Ratio (TER) of 0.47%, versus 0.5% for SBIO. IBRN is down -7.37% year-to-date (YTD) with +$2M in YTD flows. SBIO performs better with -2.11% YTD performance, and +$62M in YTD flows. Run a side-by-side ETF comparison of IBRN and SBIO below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
IBRN vs SBIO performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/16/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | IBRN SBIO | -16.95%-19.79% | -19.96%-21.19% | -7.37%-2.11% | +4.69%+18.38% | +45.93%+102.63% | n/a+15.28% |
| Flows | IBRN SBIO | --$13M | +$2M+$21M | +$2M+$62M | +$2M+$72M | +$759K+$45M | -+$6M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | IBRN SBIO | +25.01%+30.03% | +26.48%+31.82% | +25.41%+31.36% | n/a+34.09% |
| Max drawdown | IBRN SBIO | -26.38%-29.19% | -26.38%-29.19% | -34.98%-42.12% | n/a-52.50% |
| Max drawdown duration | IBRN SBIO | 58d58d | 58d58d | 338d331d | n/a1479d |
Trading data
IBRN | SBIO | |
Last sale 10/16/2026 at 1:30 PM | $29.97 | $50.12 |
| Previous close 10/15/2026 | $30.72 | $52.22 |
| Consolidated volume 10/15/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
IBRN | SBIO | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/16/2026 at 1:30 PM
Live
Closed
IBRN | SBIO | |
|---|---|---|
| Last price | $29.97 | $50.12 |
| 1D performance | -2.43% | -4.02% |
| AuM | $5.99 M | $172.67 M |
| E/R | 0.47% | 0.5% |
Characteristics
IBRN | SBIO | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | iShares | ALPS |
| Benchmark | NYSE FactSet Global Neuro Biopharma and MedTech Index | S-Network Medical Breakthroughs Index |
| N° of holdings | 69 | 104 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 24, 2022 | December 30, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
IBRN
USA
73.41%
Other
26.59%
SBIO
USA
89.31%
Other
10.69%
Sectors
IBRN
Healthcare
99.86%
Other
0.14%
SBIO
Healthcare
100.01%
Other
-0.01%
Advertisement
Diversification
IBRN
Total weight of top 15 holdings out of 15
62.03%
SBIO
Total weight of top 15 holdings out of 15
41.55%
Top 15 holdings
Data as of August 31, 2026
IBRN
Praxis Precision Medicines, Inc.
5.21%
Dianthus Therapeutics, Inc.
4.96%
ACADIA Pharmaceuticals, Inc.
4.93%
Scholar Rock Holding Corp.
4.85%
Xenon Pharmaceuticals, Inc.
4.40%
argenx SE
4.37%
Arrowhead Pharmaceuticals, Inc.
4.26%
Biogen, Inc.
4.19%
Alkermes Plc
4.15%
PTC Therapeutics, Inc.
3.70%
Denali Therapeutics, Inc.
3.56%
Neurocrine Biosciences, Inc.
3.55%
Dyne Therapeutics, Inc.
3.38%
Edgewise Therapeutics, Inc.
3.30%
Axsome Therapeutics, Inc.
3.23%
SBIO
Crinetics Pharmaceuticals, Inc.
4.60%
Apogee Therapeutics, Inc.
4.29%
CG Oncology, Inc.
3.41%
Travere Therapeutics, Inc.
3.16%
Xenon Pharmaceuticals, Inc.
2.99%
Dianthus Therapeutics, Inc.
2.96%
Oruka Therapeutics, Inc.
2.87%
ACADIA Pharmaceuticals, Inc.
2.54%
Edgewise Therapeutics, Inc.
2.31%
Definium Therapeutics, Inc.
2.23%
Dyne Therapeutics, Inc.
2.16%
Veradermics, Inc.
2.11%
Relay Therapeutics, Inc.
2.05%
Denali Therapeutics, Inc.
1.94%
Amylyx Pharmaceuticals, Inc.
1.93%
Frequently asked questions about IBRN and SBIO
How have the IBRN and SBIO ETFs performed in 2026?
As of October 16, 2026, IBRN is down -7.37% year-to-date (YTD), while SBIO has lost -2.11%. That puts SBIO better performer ahead so far this year.
Which ETF is attracting more investor money: IBRN or SBIO?
Year-to-date, the IBRN ETF saw +$2M in flows, compared to +$62M for SBIO.
Which ETF is more volatile: IBRN or SBIO?
Over the past year, IBRN had a volatility of 26.48%, while SBIO experienced 31.82%.
Which ETF is bigger: IBRN or SBIO?
As of October 16, 2026, IBRN holds $5.99 M in assets under management (AUM), while SBIO manages $172.67 M.
What sectors do the IBRN and SBIO ETFs invest in?
IBRN leans toward sectors like Healthcare. Meanwhile, SBIO focuses on Healthcare.
What are the top holdings of the IBRN ETF and SBIO ETF?
IBRN top holdings include Praxis Precision Medicines, Inc., Dianthus Therapeutics, Inc. and ACADIA Pharmaceuticals, Inc.. SBIO holds in its top three: Crinetics Pharmaceuticals, Inc., Apogee Therapeutics, Inc. and CG Oncology, Inc..
Which ETF is more diversified: IBRN or SBIO?
IBRN holds 69 securities with 62.03% of its assets in the top 15. SBIO has 104 securities and a top 15 weight of 41.55%.
Advertisement
Latest news about IBRN & SBIO
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Advertisement
Advertisement
